Abbott Laboratories announced last month it would stop distributing on Jan. 1 the prescription nonsteroidal anti-inflammatory drug Mobic--a medicine that boosted Abbott's sales following the withdrawal of Merck's cox-2 inhibitor Vioxx last year.
Abbott had been distributing Mobic for Boehringer Ingelheim and will continue to earn a commission based on Boehringer's sales, the company stated, but the distribution agreement has ended. Abbott's distribution agreement for the enlarged prostate treatment Flomax also will end Jan. 1. Abbott will continue marketing and distributing the blood pressure treatment Micardis through March 2006.
COPYRIGHT 2005 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2005 Gale Group
Contact
Home
A
Captagon